Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Profit After Tax (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Profit After Tax for 10 consecutive years, with -$12.2 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 46.31% to -$12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 92.3% year-over-year, with the annual reading at -$5.3 million for FY2025, 92.3% up from the prior year.
  • Profit After Tax for Q4 2025 was -$12.2 million at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • The five-year high for Profit After Tax was $29.4 million in Q2 2022, with the low at -$83.0 million in Q2 2021.
  • Average Profit After Tax over 5 years is -$25.1 million, with a median of -$16.2 million recorded in 2023.
  • The sharpest move saw Profit After Tax skyrocketed 135.46% in 2022, then crashed 3814.01% in 2024.
  • Over 5 years, Profit After Tax stood at -$69.9 million in 2021, then soared by 91.31% to -$6.1 million in 2022, then soared by 110.11% to $614000.0 in 2023, then plummeted by 3814.01% to -$22.8 million in 2024, then surged by 46.31% to -$12.2 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$12.2 million, $540000.0, and $247000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.